| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02876354 | Vascular Calcifications | Drug: Menaquinone | Saint-Joseph University | Phase 4 | 2016-08-01 | 2016-09-18 |
| NCT00336232 | Aging|Osteoporosis | Drug: Vitamin K | Tufts University | | 2006-05-01 | 2016-04-22 |
| NCT00931437 | Healthy | Dietary Supplement: vitamin K-rich dairy product | Maastricht University Medical Center | | 2009-04-01 | 2010-12-15 |
| NCT01094444 | Folliculitis | Other: Vitamin K3 | Per Pfeiffer|Odense University Hospital | Phase 2 | 2010-05-01 | 2015-01-20 |
| NCT00656786 | EGFR Inhibitor-associated Rash | Drug: Menadione Topical Lotion|Drug: Menadione Topical Lotion | Spectrum Pharmaceuticals, Inc | Phase 1 | 2008-04-01 | 2015-06-02 |
| NCT01143831 | Thrombosis | Dietary Supplement: Vitamin K, 20mg | Stephan Moll, MD|University of North Carolina, Chapel Hill | | 2009-11-01 | 2012-06-11 |
| NCT00785109 | Aortic Valve Calcification | Dietary Supplement: Vitamin K supplementation | RWTH Aachen University | Phase 2|Phase 3 | 2010-01-01 | 2015-09-22 |
| NCT01742273 | Cardiovascular Diseases | Drug: Vitamin K1 | RWTH Aachen University | Phase 3 | 2013-10-01 | 2015-09-21 |
| NCT01533441 | Thrombosis | Dietary Supplement: Vitamin K2 | Danisco | Phase 2 | 2012-02-01 | 2014-04-07 |
| NCT02324686 | End Stage Renal Failure on Dialysis|Atrial Fibrillation | Drug: vitamin K1 | University Health Network, Toronto | Phase 2 | 2014-01-01 | 2016-05-10 |
| NCT01972113 | Obesity|Insulin Resistance|Insulin Sensitivity|Prediabetes|Dyslipidemia|Diabetes | Dietary Supplement: Placebo-Control|Dietary Supplement: Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d)|Dietary Supplement: High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d) | Augusta University|University of Alabama at Birmingham|Yale University|Tufts University|Nattopharma ASA | Phase 1|Phase 2 | 2013-09-01 | 2016-10-11 |
| NCT02959762 | Obesity|Insulin Resistance|Obesity in Diabetes|Nutritional and Metabolic Diseases|Hyperlipidemia|Hyperglycemia|Cardiovascular Diseases | Dietary Supplement: Placebo-Control|Dietary Supplement: Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d)|Dietary Supplement: High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d) | Augusta University | Phase 1|Phase 2 | 2016-10-01 | 2016-11-07 |
| NCT01393821 | Dermatologic Complications|Malignant Neoplasm|Pain | Drug: menadione topical lotion|Other: placebo|Other: questionnaire administration|Procedure: management of therapy complications | Mayo Clinic | | 2012-01-01 | 2017-03-21 |
| NCT00990158 | Coagulation|Bleeding|Thrombosis | Drug: Phytonadione (Vitamin K1)|Drug: Placebo | St. Joseph's Healthcare Hamilton|McMaster University|University of Western Ontario, Canada | Phase 3 | 2010-07-01 | 2015-05-19 |
| NCT02517580 | Arterial Stiffness|Vitamin K2 Deficiency | Dietary Supplement: Vitamin K2 (MK7) | Lebanese American University|Omicron Pharmaceuticals | Phase 2 | 2015-03-01 | 2016-06-06 |
| NCT01675206 | Vascular Calcification | Dietary Supplement: Vitamin K2 supplementation | Rogier Caluwe|Onze Lieve Vrouw Hospital | Phase 3 | 2011-05-01 | 2012-08-25 |
| NCT01232647 | Post-Menopausal Osteoporosis | Drug: Phylloquinone|Drug: Menaquinone (MK4)|Drug: placebo | Guy's and St Thomas' NHS Foundation Trust | Phase 2|Phase 3 | 2011-04-01 | 2010-11-01 |
| NCT02278692 | Calciphylaxis|Calcific Uremic Arteriolopathy | Dietary Supplement: Vitamin K|Other: Placebo | Massachusetts General Hospital|National Kidney Foundation | | 2015-03-01 | 2017-01-25 |
| NCT02505282 | Orthostatic Hypotension | Other: Vitamin K status | University of Dundee|British Geriatrics Society | | 2012-04-01 | 2015-07-23 |
| NCT00642551 | Bone Loss|Arteriosclerosis | Dietary Supplement: menaquinone-7|Dietary Supplement: placebo | Maastricht University Medical Center | | 2008-03-01 | 2012-06-11 |
| NCT02870829 | Vascular Calcification|Systemic and Arterial Stiffness|Complication of Hemodialysis|Deficiency of Vitamin K2 | Drug: menaquinone-7 | National University Health System, Singapore|National Medical Research Council (NMRC), Singapore|Nattopharma ASA | Phase 2 | 2016-07-01 | 2016-08-16 |
| NCT01528800 | Endstage Kidney Disease | Drug: Vitamin K1|Drug: Chrystalline Lactose | Dr. Rachel Holden|Kingston General Hospital|Clinical Evaluation Research Unit at Kingston General Hospital | Phase 2 | 2012-11-01 | 2016-07-25 |
| NCT01101698 | Kidney Diseases|Coronary Artery Calcification | Drug: Vitamin K2+10g cholecalciferol|Drug: Vitamin D | Medical Universtity of Lodz | Phase 4 | 2009-06-01 | 2010-04-12 |
